Prostate Cancer, Favorable Intermediate Risk

Blood disorders & Cancer

Prostate Cancer, Favorable Intermediate Risk

Favorable intermediate-risk prostate cancer is a less aggressive form of intermediate-risk disease with a good long-term prognosis. It is defined by the presence of only one of the following risk factors:

-PSA between 10–20 ng/mL,

-Gleason score 3+4=7 (Grade Group 2), or

-Clinical stage T2b–T2c

To be considered favorable, the cancer must also meet these criteria:

-Less than 50% of biopsy cores involved

-No Gleason pattern 4+3 or higher

-No high-risk features (e.g., PSA >20, Grade Group ≥4, or stage T3 or above)

With appropriate monitoring or treatment, patients in this category have a low risk of progression, metastasis, or death from prostate cancer over the next 10–15 years.

AI Summary of Treatment Experiences

Not medical advice.

For favorable intermediate-risk prostate cancer, the main treatment options include brachytherapy, external beam radiation therapy (EBRT), radical prostatectomy, and active surveillance. Brachytherapy and EBRT are non-surgical options that deliver targeted radiation, with brachytherapy being a one-time procedure and EBRT involving multiple sessions. Radical prostatectomy is a surgical option that provides excellent cancer control and staging information but may cause side effects like urinary incontinence and erectile dysfunction. Active surveillance may be considered for select patients who wish to avoid the side effects of immediate treatment, with close monitoring for disease progression.